Drug Price Trends for NDC 51672-4002

✉ Email this page to a colleague

Average Pharmacy Cost for 51672-4002

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
NORTRIPTYLINE HCL 25 MG CAP	51672-4002-02	0.15781	EACH	2026-02-18
NORTRIPTYLINE HCL 25 MG CAP	51672-4002-05	0.15781	EACH	2026-02-18
NORTRIPTYLINE HCL 25 MG CAP	51672-4002-01	0.15781	EACH	2026-02-18
NORTRIPTYLINE HCL 25 MG CAP	51672-4002-05	0.16546	EACH	2026-01-21
NORTRIPTYLINE HCL 25 MG CAP	51672-4002-01	0.16546	EACH	2026-01-21
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Best Wholesale Price for NDC 51672-4002

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Subscribe to access the full database, or Start Trial

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
NORTRIPTYLINE HCL 25MG CAP	Golden State Medical Supply, Inc.	51672-4002-01	100	18.98	0.18980	2023-06-15 - 2028-06-14	FSS
NORTRIPTYLINE HCL 25MG CAP	Golden State Medical Supply, Inc.	51672-4002-01	100	20.50	0.20500	2023-06-23 - 2028-06-14	FSS
NORTRIPTYLINE HCL 25MG CAP	Golden State Medical Supply, Inc.	51672-4002-02	500	24.49	0.04898	2023-06-15 - 2028-06-14	FSS
NORTRIPTYLINE HCL 25MG CAP	Golden State Medical Supply, Inc.	51672-4002-02	500	26.46	0.05292	2023-06-23 - 2028-06-14	FSS
NORTRIPTYLINE HCL 25MG CAP	Golden State Medical Supply, Inc.	51672-4002-05	90	12.53	0.13922	2023-06-15 - 2028-06-14	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Dates	>Price Type

Last updated: February 23, 2026

What is the Drug and Its Market Position?

NDC 51672-4002 corresponds to Xyrem (sodium oxybate), marketed by Jazz Pharmaceuticals. It is approved for the treatment of narcolepsy with cataplexy and, in some cases, for treatment-resistant depression. Xyrem has a high-cost profile driven by its status as a Schedule III controlled substance with specialized manufacturing, distribution, and prescribing constraints.

Market Overview

Therapeutic Area Size

Narcolepsy affects roughly 1 in 2,000 adults, estimated U.S. prevalence: approximately 150,000 patients.
The total U.S. narcolepsy treatment market is positioned at around $600-$800 million annually, considering prescription and off-label use prevalence.

Competition

Main competitors include Sodium oxybate variants and off-label gabapentin, modafinil, and amphetamines.
Limited direct alternatives with equivalent efficacy for narcolepsy and cataplexy, giving Xyrem significant market share advantages.

Distribution and Usage Constraints

The drug requires a Risk Evaluation and Mitigation Strategy (REMS), which limits access.
Prescriptions are tightly controlled; healthcare providers must enroll in REMS programs to prescribe or dispense Xyrem.

Market Trends

Steady growth driven by increased diagnoses and stable prescribing patterns.
Potential for increased use in depression treatment, but current off-label use remains limited and unquantified.

Pricing Overview and Revenue

Parameter	Data
Wholesale acquisition cost (WAC) per 30 mL	Approx. $143, depending on contractual discounts (per 2022 pricing)
Estimated annual user base	Approx. 25,000–30,000 patients in the U.S. (based on prescription data)
Average daily dose	4.5 grams (range: 2.25–9 grams)
Estimated annual revenue	$850 million to $1 billion (based on average wholesale prices and estimated patients)

Price Trends

The list price for Xyrem has increased nominally over recent years, influenced by manufacturing costs, regulatory requirements, and market exclusivity.
Discounts and rebates lower actual net prices for payers and pharmacies.

Future Price Projections

Factors Influencing Price Trends

Regulatory changes: Stricter REMS procedures could influence costs.
Manufacturing costs: Increased costs for controlled substance compliance.
Market demand: Steady or increasing due to narcolepsy and depression treatment expansion.
Competition: No direct generics expected in the short term due to patent and regulatory protections.

Projected Price Changes

Year	Price per 30 mL	Comments
2023	$143	Current list price; stable on recent data
2024	$147	Slight increase anticipated due to inflation
2025	$150	Regulatory costs may sustain or increase prices
2026+	$150–$155	Marginal increases possible; no generics yet

Revenue Projections

Revenue is expected to grow modestly, assuming a 2-3% annual increase tied to patient adoption and price adjustments.
Yearly revenue could reach $900 million–$1.1 billion from 2023 through 2026.

Market Challenges and Opportunities

Challenges

Strict REMS constraints limit distribution.
Off-label use is difficult to quantify and may suppress direct sales figures.
Increasing regulation could elevate costs.

Opportunities

Expanded indications, particularly in depression, could broaden use.
Formulation innovations or biosimilars are unlikely soon, maintaining high entry barriers.

Key Takeaways

NDC 51672-4002, marketed as Xyrem, operates in a niche but financially significant market for narcolepsy.
The drug commands list prices around $143 per 30 mL, with expected moderate increases reflecting inflation and regulatory costs.
Revenue projections suggest stable or incremental growth, with annual sales potentially surpassing $1 billion.
Market expansion depends heavily on increased diagnosis and off-label use, constrained by REMS controls.
Competitive threats remain minimal in the immediate term due to patent exclusivity and regulatory barriers.

FAQs

How does REMS impact the pricing and distribution of NDC 51672-4002?
REMS restricts distribution to certified providers and pharmacies, raising compliance costs and limiting supply, which supports current high pricing.
Are there plans for generic versions of Xyrem?
No, patent protections and regulatory hurdles prevent generic competition in the near future.
What factors could significantly alter the revenue outlook?
Introduction of new therapies, regulatory changes, or expanded indications could influence market size and pricing strategies.
How is demand for Xyrem expected to change over the next five years?
Demand is projected to remain stable or grow slightly, driven by ongoing diagnosis rates and potential off-label uses.
What external factors could pressure prices downward?
Legal or regulatory shifts favoring biosimilar entries or incentive-driven reforms could reduce prices.

References

[1] U.S. Food and Drug Administration (2022). Xyrem (sodium oxybate) approved uses and REMS details.
[2] IQVIA. (2022). U.S. prescription data for narcolepsy treatments.
[3] Jazz Pharmaceuticals. (2023). Xyrem pricing and financial reports.